Next Post

Pfizer announces final phases of COVID-19 vaccine testing - The St Kitts Nevis Observer

NEW YORK — Pfizer Inc. and BioNTechSE has announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8 by an external, independent Data Monitoring Committee (DMC) […]